Who are Horizant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tarlige, Horizant, OXCARBAZEPINE, Gabitril, Cerebyx, Felbatol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gabapentin-enacarbil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Horizant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Horizant (GABAPENTIN ENACARBIL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-epileptic Agent. Area: Neuroscience.

marketed Anti-epileptic Agent Voltage-dependent calcium channel subunit alpha-2/delta-1 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Horizant (GABAPENTIN ENACARBIL) — Azurity. Horizant works by binding to the alpha-2/delta-1 subunit of voltage-dependent calcium channels, reducing the release of excitatory neurotransmitters and alleviating pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Horizant TARGET	GABAPENTIN ENACARBIL	Azurity	marketed	Anti-epileptic Agent	Voltage-dependent calcium channel subunit alpha-2/delta-1	2011-01-01
Tarlige	MIROGABALIN	Daiichi Sankyo	marketed		Voltage-dependent calcium channel subunit alpha-2/delta-1
Horizant	Horizant	University of Missouri-Columbia	marketed		Voltage-dependent calcium channel subunit alpha-2/delta-1, Voltage-dependent calcium channel subunit alpha-2/delta-2
OXCARBAZEPINE	OXCARBAZEPINE		marketed	Anti-epileptic Agent [EPC]		2000-01-01
Gabitril	TIAGABINE	Cephalon	marketed	Anti-epileptic Agent	Sodium- and chloride-dependent GABA transporter 1	1997-01-01
Cerebyx	FOSPHENYTOIN	Pfizer	marketed	Anti-epileptic Agent	Sodium channel protein type 5 subunit alpha	1996-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01

Recent regulatory actions (last 90 days)

2026-04-29 — OXCARBAZEPINE · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-epileptic Agent class)

Pfizer · 2 drugs in this class
Azurity · 1 drug in this class
Cephalon · 1 drug in this class
Novartis · 1 drug in this class
Recordati · 1 drug in this class
Viatris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Horizant — Competitive Intelligence Brief. https://druglandscape.com/ci/gabapentin-enacarbil. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing